These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 34644737

  • 1. Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis.
    Alves Júnior JM, Prota FE, Villagelin D, Bley F, Bernardo WM.
    Clinics (Sao Paulo); 2021; 76():e3271. PubMed ID: 34644737
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
    Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ, HES Mepolizumab study group.
    J Allergy Clin Immunol; 2020 Dec; 146(6):1397-1405. PubMed ID: 32956756
    [Abstract] [Full Text] [Related]

  • 3. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group.
    N Engl J Med; 2008 Mar 20; 358(12):1215-28. PubMed ID: 18344568
    [Abstract] [Full Text] [Related]

  • 4. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
    Rothenberg ME, Roufosse F, Faguer S, Gleich GJ, Steinfeld J, Yancey SW, Mavropoulou E, Kwon N, HES Mepolizumab Study Group.
    J Allergy Clin Immunol Pract; 2022 Sep 20; 10(9):2367-2374.e3. PubMed ID: 35568330
    [Abstract] [Full Text] [Related]

  • 5. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
    Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A.
    J Allergy Clin Immunol; 2010 Oct 20; 126(4):828-835.e3. PubMed ID: 20810155
    [Abstract] [Full Text] [Related]

  • 6. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
    Schwarz C, Müller T, Lau S, Parasher K, Staab D, Wahn U.
    Pediatr Allergy Immunol; 2018 Feb 20; 29(1):28-33. PubMed ID: 28986919
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
    Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD.
    J Allergy Clin Immunol; 2013 Feb 20; 131(2):461-7.e1-5. PubMed ID: 23040887
    [Abstract] [Full Text] [Related]

  • 8. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
    Gleich GJ, Roufosse F, Chupp G, Faguer S, Walz B, Reiter A, Yancey SW, Bentley JH, Steinfeld J, HES Mepolizumab Study Group.
    J Allergy Clin Immunol Pract; 2021 Dec 20; 9(12):4431-4440.e1. PubMed ID: 34389506
    [Abstract] [Full Text] [Related]

  • 9. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I.
    Cochrane Database Syst Rev; 2020 Dec 08; 12(12):CD013432. PubMed ID: 33295032
    [Abstract] [Full Text] [Related]

  • 10. Hypereosinophilic syndrome and mepolizumab.
    Verzegnassi F.
    N Engl J Med; 2008 Jun 26; 358(26):2838; author reply 2839-40. PubMed ID: 18584819
    [No Abstract] [Full Text] [Related]

  • 11. Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.
    Pane F, Lefevre G, Kwon N, Bentley JH, Yancey SW, Steinfeld J.
    Front Immunol; 2022 Jun 26; 13():935996. PubMed ID: 36091012
    [Abstract] [Full Text] [Related]

  • 12. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB, Sheikh J, Singh A.
    Curr Med Res Opin; 2010 Aug 26; 26(8):1933-46. PubMed ID: 20565230
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.
    Matucci A, Liotta F, Vivarelli E, Dies L, Annunziato F, Piccinni MP, Nencini F, Pratesi S, Maggi E, Vultaggio A.
    Front Immunol; 2018 Aug 26; 9():1198. PubMed ID: 29896203
    [Abstract] [Full Text] [Related]

  • 14. Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.
    Reiter A, Lefevre G, Cid MC, Kwon N, Mavropolou E, Yancey SW, Steinfeld J.
    Front Immunol; 2022 Aug 26; 13():840974. PubMed ID: 35493455
    [Abstract] [Full Text] [Related]

  • 15. Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance.
    Caminati M, Maule M, Benoni R, Micheletto C, Tecchio C, Vaia R, De Franceschi L, Guarnieri G, Vianello A, Senna G.
    Orphanet J Rare Dis; 2023 Sep 26; 18(1):302. PubMed ID: 37752586
    [Abstract] [Full Text] [Related]

  • 16. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008 Sep 26; 9(2):125-30. PubMed ID: 18298130
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME.
    J Allergy Clin Immunol; 2004 Jan 26; 113(1):115-9. PubMed ID: 14699394
    [Abstract] [Full Text] [Related]

  • 19. Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.
    Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD.
    N Engl J Med; 2019 Apr 04; 380(14):1336-1346. PubMed ID: 30943337
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T, Odajima H, Okamasa A, Kawase M, Komatsubara M, Mayer B, Yancey S, Ortega H.
    Allergol Int; 2017 Jul 04; 66(3):445-451. PubMed ID: 28110896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.